Connect with us

Hi, what are you looking for?

Economy

Russian drugmaker seeks vaccine emergency use

Russia’s Gamaleya Research Institute of Epidemiology has applied for emergency use authorization for its coronavirus vaccine in the Philippines, according to the local Food and Drug Administration (FDA).

The regulator, which got the application on Jan. 7, had ordered the drugmaker to submit missing documents, FDA Director-General Eric Domingo said on Friday.

Gamaleya withdrew its application for clinical trials of its vaccine on Jan. 6, the Department of Science and Technology (DoST) said.

“Their reason was simple — they would apply for emergency use authorization so they don’t need the clinical trials here,” Science and Technology Undersecretary Rowena Guevarra told an online news briefing.

US drugmaker Pfizer, Inc. and Britain’s AstraZeneca Plc have also filed for emergency use with the FDA.

The three already have existing emergency use approvals in other countries.

Meanwhile, the DoST said China National Pharmaceutical Group Co., Ltd. (Sinopharm) had yet to decide whether to pursue clinical trials for its coronavirus vaccine in the Philippines.

“Sinopharm has yet to decide if it will conduct a clinical trial here or just apply for an emergency use authorization,” DoST Assistant Secretary Leah J. Buenda told a televised public briefing in mixed English and Filipino.

Ms. Buendia said the agency had signed a confidentiality disclosure agreement with Sinopharm even if it had not yet received any data from the Chinese drugmaker. — Vann Marlo M. Villegas and Kyle Aristophere T. Atienza

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Investing

The number of businesses going bust in England and Wales jumped last month to its highest level since the start of the pandemic, as...

Economy

Co-engineered with ZEISS, new vivo X70 highlights state-of-the-art mobile photography technology Global brand vivo remains top of mind when one thinks of premium imaging...

Investing

Half of the UK’s working mothers do not get the flexibility they ask for, while those that do work flexibly face discrimination, according to...

Economy

By Jenina P. Ibañez, Reporter   Money sent home by overseas Filipino workers (OFWs) increased for the seventh straight month as more host economies with...

Economy

The Bureau of Internal Revenue (BIR) clarified that only medicines and medical devices for the treatment of coronavirus disease 2019 (COVID-19) included in an updated government list...

Economy

Typhoon Kompasu has resulted in the worst container shipping traffic jam in months, one that now stretches throughout Southeast Asia and may take weeks to unravel. ...

You May Also Like

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Economy

Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...

Investing

As a traditionally rigid insurance industry becomes bogged down by antiquated processes and operations, a handful of industry leaders are seeking to shake things...

Economy

US President Joseph R. Biden, Jr., will rely on ally countries to supply the bulk of the metals needed to build electric vehicles and focus on...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.



Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!